














BioCLIA[®] gp210 Control Set

gp210 Assay Controls

Key to Symbols Used			
	Catalog Number		Expiration Date
	For <i>In Vitro</i> Diagnostic Use		Lot Number
	Store between +2°C and +8°C		Consult Instruction for Use
	Manufacturer		Authorized Representative in European Union
	Control 1		Contains Sufficient for $< n >$ Tests
	Control 2		Chemical Risk Warning
			Biological Risk Warning

BioCLIA® gp210 Control Set

Intended Use

The BioCLIA gp210 Control Set is intended for the quality control purposes of the BioCLIA gp210 performed on the BioCLIA® 1200.

Catalog Numbers

MY00318 (2 X 1 mL)

MY00369 (4 X 1 mL)

Summary and Principles of the Procedure

Autoimmune liver diseases (ALD) include autoimmune hepatitis (AIH),^{1, 2} primary biliary cirrhosis (PBC)³ and primary sclerosing cholangitis (PSC).⁴ Determination of indicators such as AMA, CENP-B, LKM-1 and SLA/LP has significant correlation to ALD diagnosis.

Anti-gp210 antibodies can specifically bind to a 210 kDa transmembrane glycoprotein on the nuclear pore complex in the 15 amino acid residues of gp210 carboxyl terminal. Anti-gp210 antibody detection has important value for PBC diagnosis for the patients with suspected clinical, biochemical and histologic findings but anti-mitochondrial antibodies (AMAs) negative, or the ones with AMAs positive but not typical in clinical syndromes. It is present approximately 25%~30% in PBC patients.^{5, 6, 7, 8}

Materials supplied

- **gp210 Control 1** A tube contains 1mL, ready to use reagent. Control 1 contains human antibodies to gp210 in stabilizers and preservatives (Low).

gp210 Control L

Preservatives: 0.0015% < Proclin 300 < 0.6%.

- **gp210 Control 2** A tube contains 1mL, ready to use reagent. Control 2 contains human antibodies to gp210 in stabilizers and preservatives (High).

gp210 Control H

Preservatives: 0.0015% < Proclin 300 < 0.6%.

Target value and acceptable range for the controls are indicated on control information sheet in each kit.

Warnings and Precautions

The human derived material in this product was tested by FDA approved methods and found nonreactive for Hepatitis B Surface Antigen (HBsAg), Anti-HCV and HIV 1/2 antibodies. Handle as if potentially infectious.⁹ Avoid contacting with skin and eyes. Do not empty into drains. Wear suitable protective clothing.

Precautions:



Human serum is added in the controls.



Proclin 300 is added in the controls at

concentration between 0.0015% - 0.6%.

- The product is for *in vitro* diagnostic use only.
- Do not use any controls beyond their expiration dates. Do not mix controls from different lots unless specified.
- Instructions must be carefully followed for using and storing of controls. Any modification in procedure may interfere with the results. Controls and contaminated vials must be handled strictly following safety guidelines or rules of biological hazards to ensure the users' and environmental safety.
- Controls contain chemical and biological components. Avoid ingesting or splashing onto skin and mucous membrane. If direct contact with controls happens, rinse the contact surface with plenty of water immediately and see a doctor if necessary.

Storage Conditions

The kit is stable until the expiration date, if it is stored and handled as directed. Routine store the kit in refrigerator (2-8°C). Once a control tube is opened, it is good for a total of 15 times, no more than 2 hours per time when kept uncapped, onboard the instrument, after which the reagent must be discarded. Three freeze-thaw cycles before testing has no effect on the kit reagents.

Assay Procedure

Note that, for obtaining optimal performance, it is important to perform all routine maintenance procedures as defined in the BioCLIA® 1200 User Manual.

See the BioCLIA® 1200 User Manual for preparation, setup, dilutions, adjustment, assay and quality control procedures.

The control procedure can be done before running the specimens each day. Users also can adjust the control procedure period according to their own lab frequency.

Limitations

This product is designed as controls for monitoring the performance of the BioCLIA gp210. These controls are subjected to the limitations of the assay system. Deviations may indicate possible problems with one or more components in the test system.

References

1. Czaja AJ. Autoimmune liver disease. Current Opinion in Gastroenterology 2007;23:255-62.
2. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli - Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-213.
3. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti - gp210 and anti - centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27.
4. T Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert review

of gastroenterology & hepatology 2013;7:103-14.

5. ITOH S, ICHIDA T, YOSHIDA T, HAYAKAWA A, UCHIDA M, TASHIRO - ITOH T, et al. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. Journal of gastroenterology and hepatology 1998;13:257-65.

6. Nakamura M, Shimizu-Yoshida Y, Takii Y, Komori A, Yokoyama T, Ueki T, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. Journal of hepatology 2005;42:386-92.

7. Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshida Y, et al. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. Journal of autoimmunity 2006;26:138-45

8. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti - gp210 and anti - centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27.

9. Richmond JY, Mckinney RW. Biosafety in microbiological and biomedical laboratories: U.S.GPO. 1999.



HOB Biotech Group Co., Ltd

C6 Building, No. 218 Xinghu Road, Suzhou Industrial Park,

Suzhou, Jiangsu, 215123, China

REGISTRANT/MANUFACTURE: HOB Biotech Group Co., Ltd

ADDRESS/LOCATION:

C6 Building, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, 215123 China

CONTACT INFORMATION: TEL (+86)512-69561996
Fax (+86)512-62956652

WEBSITE: www.hob-biotech.com

CUSTOMER SERVICE: HOB Biotech Group Co., Ltd

CUSTOMER SERVICE CONTACT: TEL (+86)4008601202



EUROPE REPRESENTATIVE: Emergo Europe

ADDRESS/LOCATION:

Prinsessegracht 20, 2514 AP The Hague, The Netherlands

Technical Assistance

For technical assistance, contact your National Distributor.

17th April 2019

Revision 9